Infants born to women who were treated with antibodies against tumor necrosis factor alpha (TNF alpha) during pregnancy have detectable levels of antibodies until 12 months of age, according to the results of a recent study published in the journal Gastroenterology.
In this video, shared by the Mayo Clinic, Dr. Sunanda Kane shares a thorough explanation of the increased risk for adverse birth outcomes in women with inflammatory bowel disease, what that means for women and what that also could mean for the baby.
IBD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.